Search

Your search keyword '"Rodriguez Portal, J. A."' showing total 12 results
Start Over Author "Rodriguez Portal, J. A."
12 results on '"Rodriguez Portal, J. A."'

1. Lung function and radiological findings 1 year after COVID-19: a prospective follow-up

Author

Tarraso J, Safont B, Carbonell-Asins J, Fernandez-Fabrellas E, Sancho-Chust J, Naval E, Amat B, Herrera S, Ros J, Soler-Cataluna J, Rodriguez-Portal J, Andreu A, Marin M, Rodriguez-Hermosa J, Gonzalez-Villaescusa C, Soriano J, and Signes-Costa J

Subjects
Lung fibrosis, Pulmonary sequelae, COVID 19
Abstract

Background The coronavirus disease (COVID-19) pandemic has already affected more than 400 million people, with increasing numbers of survivors. These data indicate that a myriad of people may be affected by pulmonary sequelae of the infection. The aim of this study was to evaluate pulmonary sequelae in patients with bilateral COVID-19 pneumonia according to severity 1 year after hospital discharge. Methods COVID-FIBROTIC is a multicenter prospective observational cohort study for admitted patients with bilateral COVID-19 pneumonia. Pulmonary functional outcomes and chest computed tomography sequelae were analyzed 12 months after hospital discharge and we classified patients into three groups according to severity. A post hoc analysis model was designed to establish how functional test changed between groups and over time. A multivariable logistic regression model was created to study prognostic factors for lung diffusion impairment and radiological fibrotic-like changes at 12 months. Results Among 488 hospitalized patients with COVID-19 pneumonia, 284 patients had completed the entire evaluation at 12 months. Median age was 60.5 +/- 11.9 and 55.3% were men. We found between-group differences in male sex, length of hospital stay, radiological involvement and inflammatory laboratory parameters. The functional evaluation of pulmonary sequelae showed that severe patients had statistically worse levels of lung diffusion at 2 months but no between group differences were found in subsequent controls. At 12-month follow up, however, we found impaired lung diffusion in 39.8% unrelated to severity. Radiological fibrotic-like changes at 12 months were reported in 22.7% of patients (102/448), only associated with radiological involvement at admission (OR: 1.55, 95% CI 1.06-2.38; p = 0.02) and LDH (OR: 0.99, 95% CI 0.98-0.99; p = 0.046). Conclusion Our data suggest that a significant percentage of individuals would develop pulmonary sequelae after COVID 19 pneumonia, regardless of severity of the acute process. Trial registration clinicaltrials.gov NCT04409275 (June 1, 2020)

Published
2022

2. Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

Author

Wells, A. U., Flaherty, K. R., Brown, K. K., Inoue, Y., Devaraj, A., Richeldi, Luca, Moua, T., Crestani, B., Wuyts, W. A., Stowasser, S., Quaresma, M., Goeldner, R. -G., Schlenker-Herceg, R., Kolb, M., Abe, S., Aburto, M., Acosta, O., Andrews, C., Antin-Ozerkis, D., Arce, G., Arias, M., Avdeev, S., Barczyk, A., Bascom, R., Bazdyrev, E., Beirne, P., Belloli, E., Bergna, M. A., Bergot, E., Bhatt, N., Blaas, S., Bondue, B., Bonella, F., Britt, E., Buch, K., Burk, J., Cai, H., Cantin, A., Castillo Villegas, D. M., Cazaux, A., Cerri, S., Chaaban, S., Chaudhuri, N., Cottin, V., Criner, G., Dahlqvist, C., Danoff, S., Dematte D'Amico, J., Dilling, D., Elias, P., Ettinger, N., Falk, J., Fernandez Perez, E. R., Gamez-Dubuis, A., Giessel, G., Gifford, A., Glassberg, M., Glazer, C., Golden, J., Gomez Carrera, L., Guiot, J., Hallowell, R., Hayashi, H., Hetzel, J., Hirani, N., Homik, L., Hope-Gill, B., Hotchkin, D., Ichikado, K., Ilkovich, M., Izumi, S., Jassem, E., Jones, L., Jouneau, S., Kaner, R., Kang, J., Kawamura, T., Kessler, R., Kim, Y., Kishi, K., Kitamura, H., Kondoh, Y., Kono, C., Koschel, D., Kreuter, M., Kulkarni, T., Kus, J., Lebargy, F., Leon Jimenez, A., Luo, Q., Mageto, Y., Maher, T. M., Makino, S., Marchand-Adam, S., Marquette, C., Martinez, Sara, Martinez, M., Maturana Rozas, R., Miyazaki, Y., Moiseev, S., Molina-Molina, M., Malcolm, Joan Morrison, Morrow, L., Nambiar, A., Nishioka, Y., Nunes, H., Okamoto, M., Oldham, J., Otaola, M., Padilla, M., Park, J. S., Patel, N., Pesci, Riccardo, Piotrowski, W., Pitts, L., Poonyagariyagorn, H., Prasse, A., Quadrelli, S., Randerath, W., Refini, R., Reynaud-Gaubert, M., Riviere, F., Rodriguez Portal, J. A., Rosas, I., Rossman, M., Safdar, Z., Saito, T., Sakamoto, N., Salinas Fenero, M., Sauleda, J., Schmidt, S., Scholand, M. B., Schwartz, M., Shapera, S., Shlobin, O., Sigal, B., Silva Orellana, A., Skowasch, D., Song, J. W., Stieglitz, S., Stone, H., Strek, M., Suda, T., Sugiura, H., Takahashi, H., Takaya, H., Takeuchi, T., Thavarajah, K., Tolle, L., Tomassetti, S., Tomii, K., Valenzuela, C., Vancheri, C., Varone, Francesco, Veeraraghavan, S., Villar, A., Weigt, S., Wemeau, L., Wuyts, W., Xu, Z., Yakusevich, V., Yamada, Y., Yamauchi, H., Ziora, D., Richeldi L. (ORCID:0000-0001-8594-1448), Martinez R., Morrison L., Pesci A., Varone F., Wells, A. U., Flaherty, K. R., Brown, K. K., Inoue, Y., Devaraj, A., Richeldi, Luca, Moua, T., Crestani, B., Wuyts, W. A., Stowasser, S., Quaresma, M., Goeldner, R. -G., Schlenker-Herceg, R., Kolb, M., Abe, S., Aburto, M., Acosta, O., Andrews, C., Antin-Ozerkis, D., Arce, G., Arias, M., Avdeev, S., Barczyk, A., Bascom, R., Bazdyrev, E., Beirne, P., Belloli, E., Bergna, M. A., Bergot, E., Bhatt, N., Blaas, S., Bondue, B., Bonella, F., Britt, E., Buch, K., Burk, J., Cai, H., Cantin, A., Castillo Villegas, D. M., Cazaux, A., Cerri, S., Chaaban, S., Chaudhuri, N., Cottin, V., Criner, G., Dahlqvist, C., Danoff, S., Dematte D'Amico, J., Dilling, D., Elias, P., Ettinger, N., Falk, J., Fernandez Perez, E. R., Gamez-Dubuis, A., Giessel, G., Gifford, A., Glassberg, M., Glazer, C., Golden, J., Gomez Carrera, L., Guiot, J., Hallowell, R., Hayashi, H., Hetzel, J., Hirani, N., Homik, L., Hope-Gill, B., Hotchkin, D., Ichikado, K., Ilkovich, M., Izumi, S., Jassem, E., Jones, L., Jouneau, S., Kaner, R., Kang, J., Kawamura, T., Kessler, R., Kim, Y., Kishi, K., Kitamura, H., Kondoh, Y., Kono, C., Koschel, D., Kreuter, M., Kulkarni, T., Kus, J., Lebargy, F., Leon Jimenez, A., Luo, Q., Mageto, Y., Maher, T. M., Makino, S., Marchand-Adam, S., Marquette, C., Martinez, Sara, Martinez, M., Maturana Rozas, R., Miyazaki, Y., Moiseev, S., Molina-Molina, M., Malcolm, Joan Morrison, Morrow, L., Nambiar, A., Nishioka, Y., Nunes, H., Okamoto, M., Oldham, J., Otaola, M., Padilla, M., Park, J. S., Patel, N., Pesci, Riccardo, Piotrowski, W., Pitts, L., Poonyagariyagorn, H., Prasse, A., Quadrelli, S., Randerath, W., Refini, R., Reynaud-Gaubert, M., Riviere, F., Rodriguez Portal, J. A., Rosas, I., Rossman, M., Safdar, Z., Saito, T., Sakamoto, N., Salinas Fenero, M., Sauleda, J., Schmidt, S., Scholand, M. B., Schwartz, M., Shapera, S., Shlobin, O., Sigal, B., Silva Orellana, A., Skowasch, D., Song, J. W., Stieglitz, S., Stone, H., Strek, M., Suda, T., Sugiura, H., Takahashi, H., Takaya, H., Takeuchi, T., Thavarajah, K., Tolle, L., Tomassetti, S., Tomii, K., Valenzuela, C., Vancheri, C., Varone, Francesco, Veeraraghavan, S., Villar, A., Weigt, S., Wemeau, L., Wuyts, W., Xu, Z., Yakusevich, V., Yamada, Y., Yamauchi, H., Ziora, D., Richeldi L. (ORCID:0000-0001-8594-1448), Martinez R., Morrison L., Pesci A., and Varone F.

Abstract

Background: The INBUILD trial investigated the efficacy and safety of nintedanib versus placebo in patients with progressive fibrosing interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis (IPF). We aimed to establish the effects of nintedanib in subgroups based on ILD diagnosis. Methods: The INBUILD trial was a randomised, double-blind, placebo-controlled, parallel group trial done at 153 sites in 15 countries. Participants had an investigator-diagnosed fibrosing ILD other than IPF, with chest imaging features of fibrosis of more than 10% extent on high resolution CT (HRCT), forced vital capacity (FVC) of 45% or more predicted, and diffusing capacity of the lung for carbon monoxide (DLco) of at least 30% and less than 80% predicted. Participants fulfilled protocol-defined criteria for ILD progression in the 24 months before screening, despite management considered appropriate in clinical practice for the individual ILD. Participants were randomly assigned 1:1 by means of a pseudo-random number generator to receive nintedanib 150 mg twice daily or placebo for at least 52 weeks. Participants, investigators, and other personnel involved in the trial and analysis were masked to treatment assignment until after database lock. In this subgroup analysis, we assessed the rate of decline in FVC (mL/year) over 52 weeks in patients who received at least one dose of nintedanib or placebo in five prespecified subgroups based on the ILD diagnoses documented by the investigators: hypersensitivity pneumonitis, autoimmune ILDs, idiopathic non-specific interstitial pneumonia, unclassifiable idiopathic interstitial pneumonia, and other ILDs. The trial has been completed and is registered with ClinicalTrials.gov, number NCT02999178. Findings: Participants were recruited between Feb 23, 2017, and April 27, 2018. Of 663 participants who received at least one dose of nintedanib or placebo, 173 (26%) had chronic hypersensitivity pneumonitis, 170 (26%) an autoimmune IL

Published
2020

6. Variations in the prevalence across countries of chronic bronchitis and smoking habits in young adults

Author

Cerveri, I., Accordini, S., Verlato, G., Corsico, A., Zoia, M. C., Casali, L., Burney, P., de Marco, . R., Popp, for the European Community Respiratory Health Survey Study G. r. o. u. p. W., M. Abramson, J. Kutin, P. Vermeire, F. van Bastelaer, Bousquet, J., Knani, J., Neukirch, F., Liard, R., Pin, I., Pison, C., Taytard, A., Magnussen, H., Nowak, D., Wichmann, H. E., Heinrich, J., Papageorgiou, N., Avarlis, P., Gaga, M., Marossis, C., T. Gislason, D. Gislason, Prichard, J., Allwright, S., Macleod, D., Bugiani, M., Bucca, Caterina, Romano, Canzio, de Marco, R., Lo Cascio, V., Campello, C., Marinoni, A., B. Rijcken, A. Kremer, J. Crane, S. Lewis, A. Gulsvik, E. Omenaas, J. A. Marques, J. Alves, Anto`, J. M., Sunyer, J., Burgos, F., Castellsangue´, J., Roca, J., Soriano, J. B., Tobıas, A., Muniozguren, N., Ramos Gonzales, J., Capelastegui, A., Castillo, J., Rodriguez Portal, J., Martinez Moratalla, J., Almar, E., Maldonado Perez, J., Pereira, A., Sanchez, J., Quiros, J., Huerta, I., Pavo, F., Boman, G., Janson, C., Bjornsson, E., Rosenhall, L., Norrman, E., Lundback, B., Lindholm, N., Plaschke, P., Ackermann Liebrich, U., Kunzli, N., Perruchoud, A., Burr, M., Layzell, J., Hall, R., Harrison, B., Stark, J., Buist, S., Vollmer, W., and Osborne, M.

Subjects
chronic bronchitis, smoking
Published
2001

7. International variations in asthma treatment compliance

Author

Cerveri, I., Locatelli, F., Zoia, M. C., Corsico, A., Accordini, S., de Marco, R., Popp, on behalf of the ECRHS Austria: W., Abramson, A. u. s. t. r. a. l. i. a. :. M., Kutin, J., Vermeire, Belgium: P., van Bastelaer, F., Bousquet, France: J., Knani, J., Neukirch, F., Liard, R., Pin, I., Pison, C., Taytard, A., Magnussen, Germany: H., Nowak, D., Wichmann, H. E., Heinrich, J., Papageorgiou, Greece: N., Avarlis, P., Gaga, M., Marossis, C., Gislason, Iceland: T., Gislason, D., Prichard, Ireland: J., Allwright, S., Macleod, D., Bugiani, Italy: M., Bucca, Caterina, Romano, Canzio, Cascio, L., Campello, C., Marinoni, A., Casali, L., Rijcken, the Netherlands: B., Kremer, A., Crane, New Zealand: J., Lewis, S., Gulsvik, Norway: A., Omenaas, E., Marques, Portugal: J. A., Alves, J., Antoá, Spain: J. M., Sunyer, J., Burgos, F., Castellsangueâ, J., Roca, J., Soriano, J. B., Tobiáas, A., Muniozguren, N., Ramos GonzaÁles, J., Capelastegui, A., Castillo, J., Rodriguez Portal, J., Martinez Moratalla, J., Almar, E., Maldonado PeÂrez, J., Pereira, A., Saánchez, J., Quiros, J., Huerta, I., Pavo, F., Boman, Sweden: G., Janson, C., Bjornsson, E., Rosenhall, L., Norrman, E., Lundback, B., Lindholm, N., Plaschke, P., Ackermann Liebrich, Switzerland: U., Kunzli, N., Perruchoud, A., Burr, UK: M., Layzell, J., Hall, R., Harrison, B., Stark, J., Buist, USA: S., Vollmer, W., and Osborne, M.

Subjects
asthma, treatment compliance
Published
1999

8. Genes for Asthma? An Analysis of the European Community Respiratory Health Survey

Author

Burney, The European Community Respiratory Health Survey group : Co ordinating Center of : P., Chinn, S., Luczynska, C., Jarvis, D., Ait Khaled, E. L. a. i. Participating Centers: Algeria: N., Popp, Austria: W., Australia: M. Abramson, J. Kutin, Belgium: P. Vermeire, F. van Bastelaer, Denmark: R. Dahl, M. Iversen, Jögi, Estonia: R., Neukirch, France: J. Bousquet F., Pin, R. Liard I., Teculescu, C. Pison A. Taytard D., Germany: H. Magnussen, D. Nowak, J. Heinrich, H. E. Wichmann, Papageorgiou, Greece: N., Avarlis, P., Gaga, M., Marossis, C., Iceland: T. Gislason, D. Gislason, Chowgule, India: R., Prichard, I. r. e. l. a. n. d. :. J., Allwright, S., Macleod, D., Bugiani, Italy: M., Bucca, Caterina, Romano, Canzio, Marinoni, C. Campello A., Cerveri, I., Casali, L., Netherlands: B. Rijcken, A. Kremer, New Zealand: J. Crane, S. Lewis, Norway: A. Gulsvik, E. Omenaas, Avila, Portugal: R., Loureiro, R. Amaral Marques C., Chieira, C., Marques, R. Cordeiro J. A., Alves, J., Anto, Spain: J., Castellsague, J., Sunyer, J., Soriano, J., Galobardes, M., Muniozguren, J. Roca N., Ramos González, J., Castillo, A. Capelastegui J., and Rodriguez Portal, J.

Subjects
asthma, genes
Published
1997

11. Genes for asthma? An analysis of the European Community Respiratory Health Survey

Author

Burney, P., Chinn, S., Luczynska, C., Jarvis, D., Vermeire, P., Bousquet, J., Nowak, D., Prichard, J., Marco, R., Rijcken, B., Anto, J., Alves, J., Boman, G., Nielsen, N., Paoletti, P., Kesteloot, H., Ait-Khaled, N., Popp, W., Michael Abramson, Kutin, J., Bastelaer, F., Dahl, R., Iversen, M., Jögi, R., Neukirch, F., Liard, R., Pin, I., Pison, C., Taytard, A., Teculescu, D., Magnussen, H., Heinrich, J., Wichmann, H. E., Papageorgiou, N., Avarlis, P., Gaga, M., Marossis, C., Gislason, T., Gislason, D., Chowgule, R., Allwright, S., Macleod, D., Bugiani, M., Bucca, C., Romano, C., Marco Lo Cascio, R., Campello, C., Marinoni, A., Cerveri, I., Casali, L., Kresmer, A., Crane, J., Lewis, S., Gulsvik, A., Omenaas, E., Avila, R., Amaral Marques, R., Loureiro, C., Chieira, C., Cordeiro, R., Marques, J. A., Castellasague, J., Sunyer, J., Soriano, J., Galobardes, M., Roca, J., Muniozguren, N., Ramos, J., Ramos González, J., Capelastegui, A., Castillo, J., Rodriguez Portal, J., Martinez-Motatella, J., Almar, E., Maldonado Pérez, J., Pereira, A., Sánchez, J., Quiros, J., Huerta, I., Janson, C., Björnsson, E., Rosenhall, L., Norrman, E., Lundbät, B., Lindholm, N., Plaschke, P., Ackermann-Liebrich, U., Künzli, N., Perruchoud, A., Burr, M., Layzell, J., Hall, R., Harrison, B., Stark, J., Florey, C., Da Costa Pereira, A., and Wjst, M.

12. Interleukin-8 activates coagulation and correlates with survival after talc pleurodesis.

Author

Montes-Worboys A, Rodriguez-Portal JA, Arellano-Orden E, Digón-Pereiras J, and Rodriguez-Panadero F

Subjects
Adolescent, Adult, Aged, Aged, 80 and over, Female, Humans, Interleukin-8 blood, Male, Middle Aged, Pleural Effusion, Malignant blood, Survival Rate, Young Adult, Blood Coagulation, Interleukin-8 physiology, Pleural Effusion, Malignant mortality, Pleural Effusion, Malignant therapy, Pleurodesis, Talc therapeutic use
Abstract

The aim of our study was to investigate whether interleukin (IL)-8 activates systemic coagulation after talc pleurodesis in malignant pleural effusion (MPE), and whether levels of IL-8 in plasma are related to early death after talc pleurodesis. IL-8 and tumour necrosis factor (TNF)-alpha were measured in samples from 231 MPE patients before and after talc pleurodesis. Whole blood from 31 healthy volunteers was incubated with IL-8, TNF-alpha and thromboplastin for 3 h in vitro, and thrombin-antithrombin (TAT) levels were measured. The same stimulation of blood samples was repeated using doses of calibrated talc. Nine, 12 and 17 patients died within 7, 10 and 15 days respectively. IL-8 was elevated in 102 patients within 48 h, and thrombotic events were observed in six of those patients. Survival correlated inversely with IL-8 at 24 and 48 h, and a significant correlation was also found between IL-8 and TAT. A positive dose-dependent correlation with TAT production was observed when blood was stimulated with IL-8 in vitro. However, there was no significant response to stimulation with talc, as compared with control blood samples. IL-8 is involved in the activation of coagulation that may occur after talc pleurodesis, and might also be implicated in early death of patients with MPE.

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results